Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis and Sawai end Japan ciclosporin case

This article was originally published in Scrip

Executive Summary

Novartisand the Japanese generics company Sawai have agreed to end litigation relating to the immunosuppressant ciclosporin. The Swiss firm instigated legal action against Sawai in the Tokyo district court in December 2006, claiming the company's generic ciclosporin capsules infringed patents for its original branded product Neoral. Without disclosing terms, Sawai said that the action had now been halted and that sales of its product would continue unaffected.

You may also be interested in...



Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma

Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.

Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes

Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.

Related Companies

UsernamePublicRestriction

Register

SC027445

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel